Karen L. Smith's Net Worth
$6.36 Million
Who is Karen L. Smith?
Karen L. Smith has an estimated net worth of $6.36 Million. This is based on reported shares across multiple companies, which include Sucampo Pharmaceuticals, Inc., SANGAMO THERAPEUTICS, INC, ANTARES PHARMA, INC., Jazz Pharmaceuticals plc, Emergent BioSolutions Inc., Quince Therapeutics, Inc., Talaris Therapeutics, Inc., ACCELERON PHARMA INC, and Aurinia Pharmaceuticals Inc..
SEC CIK
Karen L. Smith's CIK is 0001639637
Past Insider Trading and Trends
2021 was Karen L. Smith's most active year for acquiring shares with 15 total transactions. Karen L. Smith's most active month to acquire stocks was the month of April. 2021 was Karen L. Smith's most active year for disposing of shares, totalling 19 transactions. Karen L. Smith's most active month to dispose stocks was the month of March. 2021 saw Karen L. Smith paying a total of $1,939,216.69 for 138,936 shares, this is the most they've acquired in one year. In 2021 Karen L. Smith cashed out on 63,498 shares for a total of $2,899,718.11, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Sucampo Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
SANGAMO THERAPEUTICS, INC (SGMO) Snapshot price: $0.4843
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +47.98% | 25K |
—
|
—
| 77.1K |
Jun 4
| |||
Form 4
| +36.39% | 13.9K |
—
|
—
| 52.1K |
Jun 1
| |||
Form 4
| +48.64% | 12.5K |
—
|
—
| 38.2K |
Feb 25
| |||
Form 4
| +46.86% | 8.2K |
—
|
—
| 25.7K |
Feb 25
| |||
Form 4/A
| +133.33% | 10K |
—
|
—
| 17.5K |
May 18
| |||
Form 4
| +33.33% | 2.5K |
—
|
—
| 10K |
May 18
| |||
Form 4
| +50.00% | 2.5K |
—
|
—
| 7.5K |
Jun 10
| |||
Form 4
|
∞
| 5K |
—
|
—
| 5K |
Jun 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ANTARES PHARMA, INC. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -79.64K |
$5.60 | -$446,012.00 |
0
|
May 24
| |||
Form 4
| +46.97% | 25.45K |
$4.42 | $112,497.84 | 79.64K |
Jun 10
| |||
Form 4
| +126.06% | 30.22K |
$2.73 | $82,500.60 | 54.19K |
Jun 11
| |||
Form 4
|
∞
| 23.97K |
$2.92 | $70,001.16 | 23.97K |
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Jazz Pharmaceuticals plc (JAZZ) Snapshot price: $123.21
EVP, R&D and CMO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -2.23% | -648.00 |
$143.39 | -$92,916.72 | 28.47K |
Mar 5
| |||
Form 4
| +37.88% | 8K |
—
|
—
| 29.12K |
Mar 1
| |||
Form 4
| -2.43% | -525.00 |
$147.44 | -$77,406.00 | 21.12K |
Feb 26
| |||
Form 4
| +1.70% | 359 |
$155.18 | -$99,470.38 | 21.53K |
May 11
| |||
Form 4
| +54.87% | 7.5K |
—
|
—
| 21.17K |
Mar 2
| |||
Form 4
| -4.01% | -571.00 |
$136.97 | -$78,209.87 | 13.67K |
Feb 27
| |||
Form 4
| +4.48% | 608 |
$137.10 | $83,355.51 | 14.18K |
Scheduled
|
Aug 12
| ||
Form 4
| +4.46% | 580 |
$143.63 | $83,304.82 | 13.57K |
Scheduled
|
Jul 13
| ||
Form 4
| +4.48% | 557 |
$149.61 | $83,335.11 | 12.99K |
Scheduled
|
Jun 13
| ||
Form 4
| -4.92% | -641.00 |
$148.76 | -$95,355.16 | 12.4K |
May 11
| |||
Form 4
| -0.78% | -103.00 |
$147.34 | -$15,176.02 | 13.04K |
Apr 13
| |||
Form 4
| +84.00% | 6K |
—
|
—
| 13.14K |
Feb 25
| |||
Form 4
|
∞
| 7.11K |
—
|
—
| 7.11K |
May 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Emergent BioSolutions Inc. (EBS) Snapshot price: $1.5
EVP, Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -2.50% | -305.00 |
$60.85 | -$18,559.25 | 11.89K |
May 7
| |||
Form 4
| +93.23% | 5.88K |
—
|
—
| 12.19K |
Feb 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||